New                Amsterdam Pharma

• Van Lanschot Kempen acted as Financial Adviser in connection with the European market to NewAmsterdam Pharma (the "Company") in relation to the secondary sell-down by existing shareholders in the Company on 6 June 2023
• The transaction size was upsized by more than 30% after launch of the secondary placement
• The placement of c. 15.8m ordinary shares, corresponding to c. 19% of the company’s outstanding capital, generated proceeds of USD 182m (after exercise of the over-allotment option of c. 2.1m ordinary shares) for the selling shareholders, including affiliates of Forbion Capital Partners
• Van Lanschot Kempen provided the Company, amongst others, with views on market sentiment and insights in the European investor landscape

NewAmsterdam Pharma (Nasdaq: NAMS) is a clinical-stage biotechnology company focused on improving patient care in populations with metabolic diseases where currently approved therapies have not been sufficiently successful or tolerated. Its lead candidate, obicetrapib, is an oral, low-dose and once-daily CETP inhibitor, as the currently preferred LDL-C lowering therapy to be used as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease patients.

NewAmsterdam Pharma recently completed a business combination with Frazier Lifesciences Acquisition Corporation, a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners, after which it became a Nasdaq-listed company. NewAmsterdam Pharma is based in the Netherlands.

In the last twelve months, Van Lanschot Kempen has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

• Joint Global Coordinator & Joint Bookrunner in the SEK 500 million Accelerated Bookbuild Offering by Vicore Pharma
• Joint Global Coordinator & Joint Bookrunner in the €25.0 million Capital Increase by Vivoryon Therapeutics
• Joint Global Coordinator & Joint Bookrunner in the €15.8 million Capital Increase by Sequana Medical
• Lead Manager in the DKK 1.5 billion Capital Increase by Zealand Pharma
• Capital Markets Adviser & Placement Agent in the merger between European Biotech Acquisition Corp. and Oculis SA and the connected USD 91 million PIPE
• Lead Manager in the USD 250 million US Public Offering by CureVac
• Sole Financial Adviser to GenSight Biologics in securing a €12.0 million credit facility from Heights Capital Management
• Joint Global Coordinator and Joint Bookrunner in the SEK 416 million Capital Increase by Hansa Biopharma
• Sole Financial Adviser in SynAct Pharma’s acquisition of TXP Pharma and Joint Global Coordinator & Joint Bookrunner in SynAct Pharma’s SEK 80m PIPE
• Joint Bookrunner in the SEK 200 million Accelerated Bookbuild Offering by Vicore Pharma
• Joint Global Bookrunner in the SEK 148 million Fully Guaranteed Rights Issue by Biovica
• Sole Financial Adviser to GenSight Biologics in securing a €35.0 million credit facility from the European Investment Bank (EIB)
• Joint Global Coordinator & Joint Bookrunner in the SEK 170 million Accelerated Bookbuild offering of Xbrane Biopharma
• Co-Lead Manager in the DKK 786 million Capital Increase by Zealand Pharma
• Financial Advisor in the sale of Sanquin Reagents by Sanquin Health Solutions to Gilde Healthcare
• Financial Advisor in the up to SEK 250 million (convertible) debt financing by Mendus
• Joint Global Coordinator in the SEK 299 million Directed Share Issue by BioInvent
• Sole Global Coordinator in the SEK 200 million financing consisting of a SEK 150m PIPE and a SEK 50m Fully Guaranteed Rights Issue by Abliva